← Back to searchRecruitingRecruiting
Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
NCT06852950 · Vanderbilt University Medical Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.
Eligibility criteria
Inclusion Criteria:
* Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
* Able to give informed consent
* Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
* POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
* Need glucose readings greater than or equal to one time per day
* Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone
Exclusion Criteria:
* Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
* Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
* Received chemotherapy during current hospitalization
* Planning on major surgery within 10-15 days
* Hemodialysis or peritoneal dialysis
* Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
* Vitamin C use of more than 500 milligrams per day
* Hydroxyurea use
* Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
* Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
* Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
* Skin allergy to adhesives
Study design
Enrollment target: 60 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-03-09
Estimated completion: 2027-01
Last updated: 2026-03-05
Interventions
Device: Libre 3 Plus Continuous Glucose MonitorDevice: Dexcom G7 Continuous Glucose Monitor
Primary outcomes
- • Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system (From enrollment until follow-up telephone visit 2-3 weeks after discharge)
- • Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care (From enrollment until follow-up telephone visit 2-3 weeks after discharge)
- • Questionnaire responses regarding patient familiarity with continuous glucose monitoring (From enrollment until follow-up telephone visit 2-3 weeks after discharge)
Sponsor
Vanderbilt University Medical Center · other
Contacts & investigators
ContactAngel Morvant, MD · contact · angel.morvant@vumc.org · 615-343-8332
All locations (1)
Vanderbilt University Medical CenterRecruiting
Nashville, Tennessee, United States